Aneurysm of antecubital vein: an unusual complication of peripheral intravenous cannulation

<p>Abstract</p> <p>Background</p> <p>Intravenous cannulation is a very common procedure. Venous aneurysm secondary to peripheral intravenous cannulation is extremely rare. Moreover, venous aneurysm can mimic other conditions and may confuse the issue.</p> <p>Case presentation</p> <p>We describe a case of a 45-year-old woman who was referred with the diagnosis of varicose vein of right arm. A history of intravenous cannulation at the same site was noted that raised suspicion. The swelling was compressible and turned out to be a venous aneurysm. The lesion was completely excised. Postoperative recovery was uneventful. Histology findings were in conformity with the preoperative diagnosis.</p> <p>Conclusion</p> <p>Caution should be exercised in diagnosing varicose vein at a site that bears a history of intravenous cannulation. The case also raises an important issue regarding consent. Should patients undergoing peripheral intravenous cannulation be warned of this rare complication?</p

Nicotine Chewing Gum and Group Counseling in Smoking Cessation

To the Editor: In two recent papers Tønnesen et al.12 have presented a simple and promising program for smoking cessation, which combines a pharmacologic agent (nicotine chewing gum) and psychological support (group counseling). Success is related to adjusting the strength of the nicotine chewing gum according to the individual smoker's degree of nicotine dependence. In the first study, published in the Journal (Jan. 7 issue),1 the 4-mg nicotine gum was found to be superior to the 2-mg nicotine gum for highly dependent smokers. In the second study,2 no effect of dose was found. Smokers with moderate to low degrees of

Dasiglucagon Treatment of Postprandial Hypoglycemia After Gastric Bypass: a Randomized, Double-blind, Placebo-controlled Trial

Objective: Post-bariatric hypoglycemia affects more than 50% of Roux-en-Y gastric bypass-operated individuals. Despite the often debilitating nature of this complication, existing treatment options are limited and often inefficient. Dasiglucagon is a stable glucagon analog available in a ready-to-use formulation and recently shown to mitigate post-bariatric hypoglycemia in experimental settings. Here we aimed to evaluate the hypoglycemic hindering potential of dasiglucagon in an outpatient trial.Research Design and Methods: We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital Denmark. The study included 24 Roux-en-Y gastric bypass-operated individuals (23 females) with continuous glucose monitor-verified post-bariatric hypoglycemia (≥15 minutes, Results: Compared with placebo, treatment with dasiglucagon significantly reduced time in level 1 hypoglycemia by 33% (−1.2%-points; 95% CI −2.0 to −0.5, P=0.002) and time in level 2 hypoglycemia by 54% (−0.4%-points; 95% CI −0.6 to −0.2, PConclusions: Compared with placebo, four weeks of self-administered dasiglucagon effectively reduced clinically relevant hypoglycemia in Roux-en-Y gastric bypass-operated individuals. ClinicalTrials.gov: NCT04836273.</p